Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Insulet Corporation (NASDAQ: PODD) SEC filings, offering a structured view of the company’s regulatory disclosures as a NASDAQ-listed medical device manufacturer. Insulet develops the Omnipod tubeless insulin pump platform and the Omnipod 5 Automated Insulin Delivery System, and its filings help investors understand how this business is governed, financed, and overseen.
Through Forms 10-K and 10-Q, Insulet reports audited and interim financial statements, risk factors, and management’s discussion of its Omnipod product platform, manufacturing operations, and growth strategy in automated insulin delivery and related drug delivery applications. Current reports on Form 8-K disclose material events such as quarterly financial results, amendments to incentive and severance plans, executive leadership transitions, and appointments to the board of directors and committees.
Investors can also review proxy statements for details on executive and director compensation, governance structures, and shareholder matters, as well as any registration statements related to securities offerings. For monitoring insider activity, Forms 3, 4, and 5 report beneficial ownership and changes in holdings by Insulet’s officers, directors, and other insiders, which some investors use to gauge management’s alignment with shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify important changes in financial performance, risk disclosures, compensation arrangements, or governance. Real-time updates from the SEC’s EDGAR system ensure that new Insulet filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider transaction reports, appear promptly, while AI-generated explanations make complex regulatory language more accessible to a broad range of investors and researchers.
Insulet Corporation (PODD) reported strong Q3 2025 growth. Total revenue rose to $706.3 million from $543.9 million, driven by Omnipod sales in the U.S. at $497.1 million and International at $202.1 million. Gross profit reached $510.1 million with gross margin improving to 72.2%. Net income was $87.6 million, and diluted EPS was $1.24. Operating income increased to $117.7 million as the company continued to invest in R&D ($77.2 million) and SG&A ($315.2 million) to support Omnipod 5 expansion.
Year to date, operating cash flow was $386.0 million, cash and equivalents were $757.4 million, and net debt declined as Insulet retired its 0.375% Convertible Notes and issued $450 million 6.5% senior unsecured notes; total debt, net fell to $1,014.8 million from $1,379.8 million. The board authorized up to $125 million in share repurchases; $59.6 million was executed through Q3. In ongoing litigation, a final judgment included a permanent injunction and a monetary award reduced to $59.4 million; amounts were not recorded due to pending appeals and a partial stay for certain patients.
Insulet Corporation (PODD) announced its financial results for the third quarter ended September 30, 2025. The company furnished the full details in a press release attached as Exhibit 99.1 to a Form 8-K.
The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act. Insulet’s common stock trades on The NASDAQ Stock Market under the symbol PODD.
Insulet Corp (PODD) disclosed a director equity award on Form 4. On 10/31/2025, the reporting person received an initial grant tied to 477 shares, reported as an “A” (acquisition) at $0. Following the transaction, the filer beneficially owned 477 shares, held directly.
The award was granted as restricted stock units (RSUs) that fully vest on April 30, 2026, and are settled one-for-one in shares of common stock.
Insulet Corporation (PODD) reported an initial statement of beneficial ownership on Form 3 for a company director.
The filing states beneficial ownership of 0 shares of common stock, with no derivative securities listed in the provided table. The date of event is 10/31/2025, and the form was filed by one reporting person. The submission was signed by /s/ Patricia K. Dolan, attorney-in-fact on 11/03/2025.
Insulet Corporation appointed Robbie Huffines as a Class II director, effective October 31, 2025, and named him to the Audit Committee. He will stand for election by stockholders at the 2027 Annual Meeting. Huffines previously served as Global Chair of Investment Banking and on the Executive Committee at JP Morgan Chase & Co., with a long tenure in healthcare banking.
The company states there are no arrangements under which he was selected and no related-party transactions requiring disclosure. As a non-employee director, he will receive cash and equity compensation under Insulet’s standard non-employee director program. A press release announcing the appointment was furnished as Exhibit 99.1.
Insulet Corporation reporting insider transactions by EVP & CFO Flavia Pease shows two compensation awards dated 10/01/2025. The filing records a grant of 11,708 restricted stock units (RSUs) settled one-for-one into common shares; these RSUs vest in three equal annual installments beginning one year after the grant. The filing also shows an employee stock option award to buy 1,641 shares at a strike price of $305.98, exercisable in four substantially equal annual installments and expiring 10/01/2035. After the reported RSU grant the reporting person beneficially owned 15,337 shares. Transactions were reported via a Form 4 filed 10/02/2025.
Insulet Corp (PODD) Form 144 reports a proposed sale of 1,347 common shares to be sold through Fidelity Brokerage Services on 09/16/2025 on NASDAQ, with an aggregate market value of $454,919.79. The filing shows the shares were acquired on 09/16/2025 pursuant to an option granted 02/27/2024 and payment is listed as cash. The issuer has 70,392,535 shares outstanding per the form. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
Insulet Corporation disclosed the terms of an offer letter for Flavia H. Pease in an Item 5.02 filing. Ms. Pease will receive a Prorated Annual Award split into 75% restricted stock units vesting ratably over three years and 25% stock options vesting ratably over four years. An Equity Sign-On Award will be granted as restricted stock units vesting ratably over three years. She will receive a $1,325,000 cash sign-on award. Her annual base salary will be $715,000 with a 70% target annual bonus and eligibility for severance and change-in-control benefits under the company plan. The Offer Letter is filed as Exhibit 10.1 and a related press release is dated September 16, 2025.
Insulet Corporation (PODD) Form 4 filing: The reporting person, Prem Singh (SVP, Global Operations), sold 687 shares of Insulet common stock on 09/08/2025 at a weighted average sale price of $347.49 per share (sales ranged from $347.35 to $347.51). After the reported sale, Mr. Singh beneficially owned 3,456 shares, held directly. The sale was reported by an attorney-in-fact on behalf of the reporting person and the filer offers to provide breakouts of shares sold at each price upon request.
Insulet Corporation (PODD) Form 4 shows insider transactions by Laetitia Cousin, SVP, Regulatory, Quality & Compliance, dated 09/08/2025. The filing reports the acquisition of 541 shares via an employee stock option exercisable at $276.36 and 256 shares via a separate option exercisable at $166.62, both effective 09/08/2025. The reporting person also acquired 541 and 256 shares (reported as non-derivative acquisitions) at those prices and sold 797 shares on the same date at a weighted average price of $348.81. The filing discloses that 93 of the acquired shares were purchased under the company stock purchase plan since the last Section 16 filing. Following the reported transactions, beneficial ownership figures are shown as 4,431; 4,687; and 3,890 shares on the respective lines. The transactions include annual non-qualified option awards that vest in four substantially equal annual installments.